Black Diamond (BDTX) Q2 Loss Narrows 47%

Black Diamond Therapeutics (NASDAQ:BDTX), a biotechnology developer focused on precision cancer therapies, reported its financial results for the second quarter of fiscal 2025 on August 7, 2025. The most notable takeaway was a marked improvement in financial efficiency: net loss per share (GAAP) narrowed to $0.19, surpassing the consensus analyst estimate of $(0.25). The company posted no revenue, in line with expectations. The period’s strong cost discipline led to decreased research and administrative expenses. A cash position of $142.8 million (GAAP, as of Q2 2025) extends the operating runway well into late 2027. Overall, the quarter was marked by progress in clinical milestones and improved operational efficiency, though revenue remains absent and future value centers on the upcoming silevertinib clinical results. Source: Analyst estimates for the quarter provided by FactSet. Black Diamond Therapeutics focuses on developing targeted therapies for cancers defined by specific genetic mutations. Its leading product candidate is silevertinib (BDTX-1535), a brain-penetrant small-molecule epidermal growth factor receptor (EGFR) inhibitor intended to address non-small cell lung cancer and glioblastoma, two aggressive forms of cancer with unmet medical needs. The company has refined its pipeline by outlicensing other assets, most notably BDTX-4933, to concentrate resources on silevertinib.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool